Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Resolute Mining executives released after paying $180 million to resolve tax dispute with Mali government, highlighting tensions between mining companies and the Malian authorities.
Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Resolute Mining executives released after paying $180 million to resolve tax dispute with Mali government, highlighting tensions between mining companies and the Malian authorities.